vs
Side-by-side financial comparison of Baxter International (BAX) and Mobileye Global Inc. (MBLY). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $1.9B, roughly 1.5× Mobileye Global Inc.). On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 27.4%). Over the past eight quarters, Mobileye Global Inc.'s revenue compounded faster (109.9% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Mobileye Global Inc. is a United States-domiciled, Israel-headquartered autonomous driving company. It is developing self-driving technologies and advanced driver-assistance systems (ADAS) including cameras, computer chips, and software. Mobileye was acquired by Intel in 2017 and went public again in 2022.
BAX vs MBLY — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $1.9B |
| Net Profit | $-1.1B | — |
| Gross Margin | 19.4% | 14.2% |
| Operating Margin | -24.5% | — |
| Net Margin | -37.9% | — |
| Revenue YoY | 458.0% | 27.4% |
| Net Profit YoY | -120.3% | — |
| EPS (diluted) | $-2.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.9B | ||
| Q4 25 | $3.0B | $446.0M | ||
| Q3 25 | $2.8B | $504.0M | ||
| Q2 25 | $2.8B | $506.0M | ||
| Q1 25 | $2.6B | $438.0M | ||
| Q4 24 | $533.0M | $490.0M | ||
| Q3 24 | $2.7B | $486.0M | ||
| Q2 24 | $3.8B | $439.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.1B | $-127.0M | ||
| Q3 25 | $-46.0M | $-96.0M | ||
| Q2 25 | $91.0M | $-67.0M | ||
| Q1 25 | $126.0M | $-102.0M | ||
| Q4 24 | $-512.0M | $-71.0M | ||
| Q3 24 | $140.0M | $-2.7B | ||
| Q2 24 | $-314.0M | $-86.0M |
| Q1 26 | — | 14.2% | ||
| Q4 25 | 19.4% | 45.3% | ||
| Q3 25 | 33.5% | 48.2% | ||
| Q2 25 | 35.3% | 49.8% | ||
| Q1 25 | 32.8% | 47.3% | ||
| Q4 24 | 25.0% | 49.2% | ||
| Q3 24 | 38.3% | 48.8% | ||
| Q2 24 | 37.5% | 47.6% |
| Q1 26 | — | — | ||
| Q4 25 | -24.5% | -31.4% | ||
| Q3 25 | 6.1% | -21.6% | ||
| Q2 25 | 6.8% | -14.6% | ||
| Q1 25 | 2.2% | -26.7% | ||
| Q4 24 | -25.5% | -17.6% | ||
| Q3 24 | 5.7% | -577.6% | ||
| Q2 24 | -5.0% | -21.4% |
| Q1 26 | — | — | ||
| Q4 25 | -37.9% | -28.5% | ||
| Q3 25 | -1.6% | -19.0% | ||
| Q2 25 | 3.2% | -13.2% | ||
| Q1 25 | 4.8% | -23.3% | ||
| Q4 24 | -96.1% | -14.5% | ||
| Q3 24 | 5.2% | -558.6% | ||
| Q2 24 | -8.2% | -19.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-2.21 | $-0.15 | ||
| Q3 25 | $-0.09 | $-0.12 | ||
| Q2 25 | $0.18 | $-0.08 | ||
| Q1 25 | $0.25 | $-0.13 | ||
| Q4 24 | $-0.99 | $-0.09 | ||
| Q3 24 | $0.27 | $-3.35 | ||
| Q2 24 | $-0.62 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $1.2B |
| Total DebtLower is stronger | $9.5B | — |
| Stockholders' EquityBook value | $6.1B | $8.2B |
| Total Assets | $20.1B | $8.7B |
| Debt / EquityLower = less leverage | 1.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.0B | $1.8B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.7B | $1.7B | ||
| Q1 25 | $2.3B | $1.5B | ||
| Q4 24 | $1.8B | $1.4B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $2.1B | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $6.1B | $11.9B | ||
| Q3 25 | $7.2B | $11.9B | ||
| Q2 25 | $7.3B | $12.1B | ||
| Q1 25 | $7.1B | $12.0B | ||
| Q4 24 | $7.0B | $12.1B | ||
| Q3 24 | $7.9B | $12.1B | ||
| Q2 24 | $7.6B | $14.7B |
| Q1 26 | — | $8.7B | ||
| Q4 25 | $20.1B | $12.5B | ||
| Q3 25 | $21.1B | $12.5B | ||
| Q2 25 | $21.0B | $12.6B | ||
| Q1 25 | $21.3B | $12.5B | ||
| Q4 24 | $25.8B | $12.6B | ||
| Q3 24 | $26.7B | $12.6B | ||
| Q2 24 | $26.3B | $15.3B |
| Q1 26 | — | — | ||
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $75.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $75.0M | ||
| Q4 25 | $584.0M | $113.0M | ||
| Q3 25 | $237.0M | $167.0M | ||
| Q2 25 | $217.0M | $213.0M | ||
| Q1 25 | $-193.0M | $109.0M | ||
| Q4 24 | $488.0M | $204.0M | ||
| Q3 24 | $253.0M | $126.0M | ||
| Q2 24 | $115.0M | $30.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $86.0M | ||
| Q3 25 | — | $143.0M | ||
| Q2 25 | — | $199.0M | ||
| Q1 25 | — | $95.0M | ||
| Q4 24 | — | $191.0M | ||
| Q3 24 | — | $104.0M | ||
| Q2 24 | — | $6.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.3% | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | 39.3% | ||
| Q1 25 | — | 21.7% | ||
| Q4 24 | — | 39.0% | ||
| Q3 24 | — | 21.4% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.38× | — | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
MBLY
Segment breakdown not available.
